At a glance
- Originator Otsuka Pharmaceutical
- Class Antihyperlipidaemics; Sesquiterpenes
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Transplant rejection
Most Recent Events
- 19 Apr 1996 Discontinued-Preclinical for Immunological disorders in Japan (Unknown route)
- 28 Jul 1995 Discontinued-Preclinical for Transplant rejection in Japan (Unknown route)